VOYA Investment Management
SPRY icon

VOYA Investment Management’s ARS Pharmaceuticals SPRY Stock Holding History

VOYA Investment Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$481K Buy
60,110
+1,737
+3% +$14.9K ﹤0.01% 1848
2026
Q1 		$469K Buy
58,373
+24,245
+71% +$232K ﹤0.01% 1743
2025
Q4 		$398K Sell
34,128
-80,725
-70% -$785K ﹤0.01% 1850
2025
Q3 		$1.15M Sell
114,853
-51,331
-31% -$737K ﹤0.01% 1433
2025
Q2 		$2.9M Buy
166,184
+100,461
+153% +$1.45M ﹤0.01% 1156
2025
Q1 		$827K Sell
65,723
-1,554
-2% -$18.7K ﹤0.01% 1650
2024
Q4 		$710K Buy
67,277
+19,381
+40% +$271K ﹤0.01% 1782
2024
Q3 		$694K Buy
47,896
+30,589
+177% +$364K ﹤0.01% 1824
2024
Q2 		$147K Buy
+17,307
New +$154K ﹤0.01% 2566
2021
Q2 		– Sell
-5,350
Closed -$233K – 2892
2021
Q1 		$233K Buy
+5,350
New +$253K ﹤0.01% 2450

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

VOYA Investment Management's SPRY Position: Q2 2026 in Review

VOYA Investment Management increased its ARS Pharmaceuticals (SPRY) stake by 3% in Q2 2026, buying an estimated $14.9K and bringing the position to 60,110 shares worth $481K. The position accounts for ﹤0.01% of the portfolio, ranked #1848.

VOYA Investment Management first reported a position in SPRY in Q1 2021 and has held it in 10 quarters since. The position peaked at $2.9M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • VOYA Investment Management held 60,110 shares of ARS Pharmaceuticals worth $481K as of Q2 2026.
  • VOYA Investment Management bought 1,737 ARS Pharmaceuticals shares in Q2 2026, an estimated $14.9K.
  • ARS Pharmaceuticals made up ﹤0.01% of VOYA Investment Management's portfolio in Q2 2026, its #1848 holding.
  • VOYA Investment Management first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 10 quarters since.
  • VOYA Investment Management's ARS Pharmaceuticals position peaked at $2.9M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on VOYA Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.